Genomic Analysis for Advanced Lung Cancer
Trial Summary
What is the purpose of this trial?
This research trial studies comprehensive genomic analysis in tissue samples from patients with non-small cell lung cancer that has come back or is stage IV. Comprehensive genomic analysis may identify specific gene mutations (changes in deoxyribonucleic acid \[DNA\]) and help doctors to tailor treatment to target the specific mutations.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Comprehensive Genomic Analysis for advanced lung cancer?
Comprehensive Genomic Profiling (CGP) helps identify specific genetic changes in lung cancer, which can guide doctors to choose targeted treatments that are more likely to work for each patient. Studies show that CGP can find treatment options when standard tests do not, and it aligns with guidelines for testing certain genetic markers in lung cancer.12345
Is genomic analysis for lung cancer safe for humans?
How is Comprehensive Genomic Analysis different from other treatments for advanced lung cancer?
Comprehensive Genomic Analysis (CGA) is unique because it uses next-generation sequencing (NGS) to identify specific genetic changes in a patient's cancer, allowing for personalized treatment plans. This approach is particularly beneficial when standard molecular tests do not find actionable targets, offering a tailored therapy option based on the individual's unique cancer profile.12789
Eligibility Criteria
This trial is for adults with stage IV or recurrent non-small cell lung cancer who have a life expectancy of at least 3 months and are in relatively good health. They must not have had recent serious heart issues, active hepatitis, HIV, or other cancers that could affect the outcome. Pregnant women are excluded.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Genomic Analysis
Patients undergo collection of tissue samples for genomic analysis via mass spectrometry, PCR, and microarray
Treatment
Patients may begin therapy based on the results of the genomic analysis
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Comprehensive Genomic Analysis (Genomic Analysis)
Comprehensive Genomic Analysis is already approved in European Union, United States, Canada, Japan for the following indications:
- Identification of specific gene mutations in non-small cell lung cancer
- Identification of specific gene mutations in non-small cell lung cancer
- Identification of specific gene mutations in non-small cell lung cancer
- Identification of specific gene mutations in non-small cell lung cancer